During the past decade, Clinique des maladies Lipidiques de Quebec conducted 13 clinical trials. In the 10-year time frame, 13 clinical trials started and 14 clinical trials were completed, i.e. on average, 107.7% percent of trials that started reached the finish line to date. In the past 5 years, 9 clinical trials started and 2 clinical trials were completed. i.e. 22.2% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Clinique des maladies Lipidiques de Quebec" #1 sponsor was "Pfizer" with 8 trials, followed by "Ionis Pharmaceuticals, Inc." with 6 trials sponsored, "Acasti Pharma Inc." with 2 trials sponsored, "Arrowhead Pharmaceuticals" with 2 trials sponsored and "Boehringer Ingelheim" with 2 trials sponsored. Other sponsors include 3 different institutions and companies that sponsored additional 12 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Clinique des maladies Lipidiques de Quebec" #1 collaborator was "Eli Lilly and Company" with 2 trials as a collaborator, "JSS Medical Research Inc." with 2 trials as a collaborator, "Abbott" with 1 trials as a collaborator, "Akcea Therapeutics" with 1 trials as a collaborator and "Brigham and Women's Hospital" with 1 trials as a collaborator. Other collaborators include -3 different institutions and companies that were collaborators in the rest 7 trials.

According to Clinical.Site data, the most researched conditions in "Clinique des maladies Lipidiques de Quebec" are "Hypertriglyceridemia" (5 trials), "Dyslipidemia" (3 trials), "Familial Chylomicronemia Syndrome" (3 trials), "Hypercholesterolemia" (3 trials) and "Cardiovascular Disease" (2 trials). Many other conditions were trialed in "Clinique des maladies Lipidiques de Quebec" in a lesser frequency.

Most popular intervention types in "Clinique des maladies Lipidiques de Quebec" are "Drug" (28 trials), "Other" (7 trials), "Biological" (1 trials) and "Dietary Supplement" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (20 trials), "Olezarsen" (5 trials), "Bococizumab (PF-04950615;RN316)" (2 trials), "PF-04950615 (RN316)" (2 trials) and "bococizumab (PF-04950615)" (2 trials). Other intervention names were less common.

The vast majority of trials in "Clinique des maladies Lipidiques de Quebec" are 28 trials for "All" genders.

Currently, there are NaN active trials in "Clinique des maladies Lipidiques de Quebec". undefined are not yet recruiting, 5 are recruiting, 3 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 15 completed trials in Clinique des maladies Lipidiques de Quebec, undefined suspended trials, and 5 terminated clinical trials to date.

Out of the total trials that were conducted in Clinique des maladies Lipidiques de Quebec, 0 "Phase 1" clinical trials were conducted, 12 "Phase 2" clinical trials and 14 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 2 trials, and there were also 0 trials that are defined as “Not Applicable".